Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416837 | 1.00 | ACHE (1.00) | ACHEBCHEMEN1USP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30600296 | 0.98 | MEN1 (1.00) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL9540233 | 0.93 | ACHE (1.00) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8970452 | 0.77 | ACHE (0.89) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8969414 | 0.77 | ACHE (0.62) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8969953 | 0.77 | ACHE (0.62) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8969190 | 0.77 | ACHE (0.89) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8969749 | 0.76 | ACHE (0.60) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL13657721 | 0.74 | ACHE (0.62) | ACHEBCHEMEN1USP2ALDH1A1 | |
| SCHEMBL8969338 | 0.73 | ACHE (0.89) | ACHEBCHEMEN1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2686320-B1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| WO-2014043272-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | TRIUS THERAPEUTICS INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20040132751-A1 | Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops | HF ARZNEIMITTELFORSCHUNG GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1404341-A1 | ACTIVE SUBSTANCE COMBINATION FOR MEDICAMENTOUS THERAPY OF NICOTINE DEPENDENCY | HF ARZNEIMITTELFORSCHUNG GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-6627631-B1 | Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuous and controlled manner. The pharmaceutical administration form | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2003-09-30 | — | — | US | disclosed |
| US-6599511-B1 | Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2003-07-29 | — | — | US | disclosed |
| US-6558696-B1 | Storage stable transdermal therapeutic system for controlled release of 1,2,3,9-tetrahydropyrrolo(2,1-b)quinazoline; alzheimer's disease | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2003-05-06 | — | — | US | disclosed |
| US-6558696-B1 | Storage stable transdermal therapeutic system for controlled release of 1,2,3,9-tetrahydropyrrolo(2,1-b)quinazoline; alzheimer's disease | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2003007966-A1 | ACTIVE SUBSTANCE COMBINATION FOR MEDICAMENTOUS THERAPY OF NICOTINE DEPENDENCY | HF ARZNEIMITTELFORSCHUNG GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
| EP-1152763-B1 | USE OF DESOXYPEGANINE FOR THE TREATMENT OF DRUG DEPENDENCE | LOHMANN THERAPIE SYST LTS (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1152751-A1 | DESOXYPEGANINE TRANSDERMAL THERAPEUTIC SYSTEM | LTS Lohmann Therapie-Systeme AG (DE) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000048579-A1 | DESOXYPEGANINE TRANSDERMAL THERAPEUTIC SYSTEM | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACHE 1285/4885BCHE 947/4885MEN1 3398/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACHE 971/4885BCHE 731/4885MEN1 3481/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | ACHE 1285/4885BCHE 947/4885MEN1 3398/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | ACHE 1285/4885BCHE 947/4885MEN1 3398/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | ACHE 971/4885BCHE 731/4885MEN1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.